MEDIA RELEASES
Crassula Pharmaceuticals Launches Vascutan, Irbesartan, in Honduras
Crassula Introduces Vascutan for Advanced Hypertension Control in Honduras Tegucigalpa, Honduras – Crassula Pharmaceuticals, a leader in cardiovascular healthcare solutions, is thrilled to announce the market introduction of Vascutan, an Irbesartan-based medication, in Honduras. This strategic expansion of Crassula’s cardiovascular portfolio underscores the company’s commitment to combating hypertension and associated cardiac conditions. Irbesartan, the active ingredient in Vascutan, is a
We are proud to announce a new addition to our team at CRASSULA!
We are proud to announce a new addition to our team at CRASSULA! We are thrilled to announce an exciting new addition to our team at CRASSULA! Please join us in welcoming Daniel Suazo as the new Medical Representative Lead at #CrassulaHonduras. Daniel comes to us with an impressive background in the healthcare sector, where he has consistently demonstrated exceptional
Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras
Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras Crassula Honduras Announces the Launch of Glycedil, Sitagliptin 100mg, in Honduras Tegucigalpa, Honduras – In a significant expansion of its diabetes care portfolio, Crassula Pharmaceuticals proudly introduces Glycedil, a Sitagliptin 100mg tablet, to the Honduran market. This strategic launch underscores Crassula’s unwavering commitment to innovating in the field of chronic disease
Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras
Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras Crassula Pharmaceuticals Launches Relixib, Etoricoxib 120mg, in Honduras Tegucigalpa, Honduras – Crassula Honduras, a leading pharmaceutical manufacturer renowned for its commitment to quality, is excited to announce the introduction of Relixib, an etoricoxib 120mg tablet, to the Honduran market. This new addition to Crassula’s portfolio reinforces the company’s dedication to providing
Dr. Bhavana Gupta
Crassula Pharmaceuticals Welcomes Crassula is thrilled to announce the appointment of Dr. Bhavana Gupta as its new Chief Technical Officer (CTO). Dr. Gupta will be at the forefront of managing the technical operations of the company, including overseeing the research and development department. Her role will also encompass serving as a vital technical advisor, directly reporting to Mr. Roopesh Gupta,
Cancer Remains A Threat In The Society
Cancer Remains A Threat In The Society Cancer is caused by disturbances in cell growth and behavior. In a healthy body, new white blood cells are regularly produced to replace old, dying blood cells. Blood cancer is caused by excessive production of white blood cells in the bone marrow. Why Is Cancer Still Growing?The biggest threats related to climate change
Noncommunicable diseases (NCDs)
Noncommunicable diseases (NCDs) Tackling Noncommunicable Diseases: A Global Health Priority Noncommunicable diseases (NCDs), including cancer, heart disease, and diabetes, are among the most prevalent and rapidly escalating health issues facing society today. These conditions, characterized by their non-transmissible nature, contribute to approximately three-quarters of all global deaths, highlighting a significant public health challenge. Alarmingly, about 77% of NCD-related fatalities occur
Crassula Pharma Lauches In Honduras
Crassula Pharmaceuticals Launches in Honduras Crassula Pharmaceuticals Launches Gasflum, Esomeprazole 40mg Coated Tablet, in Honduras Tegucigalpa, Honduras – Crassula Honduras, a premier pharmaceutical manufacturer, proudly announces the launch of Gasflum, an esomeprazole 40mg coated tablet, enhancing its portfolio of high-quality healthcare solutions in Honduras. Designed for effective management of acid reflux and related conditions, Gasflum offers a significant advancement in
